EquiReason

EquiReason research coverage

Ovid Therapeutics Inc. OVID

Healthcare · Drug Manufacturers - General

24quarters analysed
12SEC filings read
1segments identified
10institutional managers tracked

Segments it reports

The business segments Ovid Therapeutics Inc. reports in its own SEC filings.

  • Reportable Segment

Product lines it reports

The product and service lines Ovid Therapeutics Inc. breaks its revenue into.

  • Royalty License And Termination Agreement

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements27
  • Quarterly metric series12
  • Business segments1
  • SEC filings12
  • Deals and transactions1
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings quality checks5
  • Estimate revisions11
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Cash flow series24
  • Earnings series24
  • Operating cash flow series24
  • Guidance changesnot found
  • Margin seriesnot found
  • Per-share seriesnot found

This page says how much of Ovid Therapeutics Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open OVID in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Ovid Therapeutics Inc. (OVID) — research coverage | EquiReason